V. Martelli

Research Field

588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study

Annals of Oncology (2024)

V. Martelli J. Vidal Barrull Caridad Fernández Rodríguez Rodrigo de Almeida Toledo Joan Gibert

Acquired resistance

EGFR Inhibitors

10.1016/j.annonc.2024.08.657

Cite

Citations (0)

Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.

PubMed (1994)

F Nocentini L Gugliotta Lucia Catani Nicola Vianelli S Baravelli

The hemostatic toxicity of low dose L-asparaginase from Erwinia carotovora (Erwinase) has been reported to be negligible in adult patients with acute lymphoblastic leukemia (ALL); conversely, no consistent data have been obtained when Erwinase is administered at intermediate doses. We report preliminary clinical and laboratory hemostatic data from 10 adult patients with ALL treated during induction phase with intermediate doses of Erwinase (20,000 IU/m2s.c. every other day, for a total of six administrations). No thrombotic or hemorrhagic events were registered and the mean values of PT, aPTT, fibrinogen, antithrombin and D-dimer did not change during treatment. Only one patient showed a decrease of antithrombin (48% on day 8) requiring temporary suspension of Erwinase therapy. These data suggest that intermediate doses of Erwinase also have negligible hemostatic toxicity in adult patients with ALL.

Asparaginase

Acute lymphocytic leukemia

Source

Cite

Citations (7)

118: Elevated CD14+ Cell Dose in Marrow Graft Correlates with Increased Mortality after Allogeneic Transplantation

Biology of Blood and Marrow Transplantation (2008)

Mario Arpinati Gabriella Chirumbolo Benedetta Nicolini Antonio De Vivo Francesca Bonifazi

that included all autologous HPC Transplant (HPCT) patients with hematological malignancies seen by our HPCT program from February 2003 to January 2007.Costs were compiled from the Institution's Charge Description Master and included costs from additional filgrastim administration through collection.The threshold was increased incrementally from 4 to 9 CD341 cells/ml to determine the most cost effective strategies while maximizing the number of successful collections.Results: There were 302 autologous patients with 463 peripheral CD34 assays and 572 collections.Of these, 149 patients and 322 observations had CD341 counts \21 CD341 cells/ml.175/322 were assays with collections, while 147 were assay only.The analysis of the decision tree indicates that at a CD341 level of 7, the costs of the collection are moderately reduced by 3.3%, and 87% of the patients meet the minimum cell goal.At a level of 8 CD341 cells/ml, the costs are reduced 4.5% and 100% of patients meet the minimum cell goal.Discussion: The results suggest that the most cost effective collection occurs at peripheral CD341 count of 8 CD341 cells/ml or above.This is not unexpected, as better collectors have fewer collections.However, this results in an unacceptably high number of patients that will fail to collect.

10.1016/j.bbmt.2007.12.127

Cite

Citations (0)

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

Experimental Hematology (2002)

Francesca Re Mario Arpinati Nicoletta Testoni Paolo F. Ricci Carolina Terragna

CD86

CD80

Immunophenotyping

CD11c

10.1016/s0301-472x(01)00768-8

Cite